Reviewing the amendment protocol of the AstraZeneca's fixed dose combination (FDC) Zibotentan plus Dapagliflozin, the Subject ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending Forxiga (dapagliflozin) as an option to treat chronic ...

The “somewhat unexpected” finding is likely related to the profound impact on health status from the procedure itself.

Use of the AstraZeneca Dapagliflozin Patient Identification Resource (DAPA-id) to identify patients in your practice who may benefit from taking dapagliflozin. • Opportunities to improve your practice ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

AstraZeneca manufactures Farxiga, one of the drugs selected in the first round of drug price negotiations under the Program. Farxiga (dapagliflozin) is used to treat diabetes, heart disease ...

AstraZeneca's Farxiga reduced the risk of ... The study showed that treatment with Farxiga (dapagliflozin) led to an 18% reduction in cardiovascular death or worsening heart failure in patients ...

AstraZeneca’s legal challenge to Medicare ... and chronic kidney disease therapy Farxiga (dapagliflozin). The decision is an early win for the Biden administration in its defense of a series ...

AstraZeneca, as part of its ongoing $3.5 billion investment in American innovation, opened its first U.S.-operated cell therapy factory in Maryland to help treat cancer patients. The U.K-based ...

HEADQUARTERS IN ROCKVILLE. THIS LAB ISN’T OPEN OR OPERATIONAL YET, BUT ONCE IT IS, THE FOLKS AT ASTRAZENECA BELIEVE IT IS GOING TO REVOLUTIONIZE CANCER TREATMENT. IT GIVES US HOPE. I MEAN.